Skip to main content

Advertisement

SpringerLink
Log in

Chinese guidelines for treatment of adult primary immune thrombocytopenia

  • Guide Line
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Primary immune thrombocytopenia (ITP) is a bleeding disorder commonly encountered in clinical practice. The International Working Group (IWG) on ITP has published several landmark papers on terminology, definitions, outcome criteria, bleeding assessment, diagnosis, and management of ITP. The Chinese consensus reports for diagnosis and management of adult ITP have been updated to the 4th edition. Based on current consensus positions and new emerging clinical evidence, the thrombosis and hemostasis group of the Chinese Society of Hematology issued Chinese guidelines for management of adult ITP, which aim to provide evidence-based recommendations for clinical decision making.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85(3):174–80.

    PubMed  Google Scholar 

  2. Terrell DR, Beebe LA, Neas BR, Vesely SK, Segal JB, George JN. Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol. 2012;87(9):848–52.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308–15.

    Article  PubMed  CAS  Google Scholar 

  4. British Committee for Standards in Haematology General Haematology. Task F: guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574–96.

    Article  Google Scholar 

  5. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86.

    Article  PubMed  CAS  Google Scholar 

  6. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207.

    Article  PubMed  CAS  Google Scholar 

  7. Chinese Society of Hematology GoTaH. Consensus Of Chinese Specialists On the diagnosis and treatment of the adult primary immune thrombocytopenia. Chin J Hematol. 2012;33(11):975–7.

    Google Scholar 

  8. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–93.

    Article  PubMed  CAS  Google Scholar 

  9. Thrombosis, Hemostasis Group HSCMA. Consensus of Chinese experts on diagnosis and treatment of adult primary immune thrombocytopenia (version 2016). Zhonghua Xue Ye Xue Za Zhi. 2016;37(2):89–93.

    Google Scholar 

  10. Wang XQ. Prospective clinical study of diagnosis and classification for 282 cases with primary myelodysplastic syndrome. Zhonghua Xue Ye Xue Za Zhi. 2006;27(8):546–9.

    PubMed  Google Scholar 

  11. Kuendgen A, Matsuda A, Germing U. Differences in epidemiology of MDS between Western and Eastern countries: ethnic differences or environmental influence? Leuk Res. 2007;31(1):103–4.

    Article  PubMed  Google Scholar 

  12. Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of aplastic anemia (2017. Zhonghua Xue Ye Xue Za Zhi. 2017;38(1):1–5.

    Google Scholar 

  13. Salama A, Rieke M, Kiesewetter H, von Depka M. Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature. Ann Hematol. 2009;88(1):11–5.

    Article  PubMed  CAS  Google Scholar 

  14. Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016;127(3):296–302 (quiz 370).

    Article  PubMed  CAS  Google Scholar 

  15. Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109(4):1401–7.

    Article  PubMed  CAS  Google Scholar 

  16. Matschke J, Muller-Beissenhirtz H, Novotny J, Vester I, Hertenstein B, Eisele L, et al. A randomized trial of daily prednisone versus pulsed dexamethasone in treatment-naive adult patients with immune thrombocytopenia: EIS 2002 study. Acta Haematol. 2016;136(2):101–7.

    Article  PubMed  CAS  Google Scholar 

  17. Ben-Yehuda D, Gillis S, Eldor A. Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. Acta Haematol. 1994;91(1):1–6.

    Article  PubMed  CAS  Google Scholar 

  18. Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the cooperative latin american group on hemostasis and thrombosis. Blood. 1984;64(6):1179–83.

    PubMed  CAS  Google Scholar 

  19. Wang S, Yang R, Zou P, Hou M, Wu D, Shen Z, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol. 2012;96(2):222–8.

    Article  PubMed  CAS  Google Scholar 

  20. Wang M, Liu YF, Sun H, Xie XS, Ma J, Gan SL, et al. Clinical analysis of recombinant human thrombopoietin for treatment of 46 adult patients with newly diagnosed primary immune thrombocytopenia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(2):531–5.

    PubMed  Google Scholar 

  21. Liu X, Huang Y, Liu W, Chen Y, Xue F, Zhang L, et al. Clinical analysis of recombinant human thrombopoietin for 92 adults with severe primary immune thrombocytopenia. Zhonghua Xue Ye Xue Za Zhi. 2015;36(4):312–5.

    PubMed  CAS  Google Scholar 

  22. Hua B, Zhao Y, Wang S, Zhu T, Zhao Y. Development of recombinant human thrombopoietin antibodies following multi-dosing, subcutaneously medication in thrombocytopenic patients. Chin J Thromb Hemostasis. 2005;11(2):59–61.

    Google Scholar 

  23. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–47.

    Article  PubMed  CAS  Google Scholar 

  24. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2009;373(9664):641–8.

    Article  CAS  Google Scholar 

  25. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet (London, England). 2011;377(9763):393–402.

    Article  CAS  Google Scholar 

  26. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537–45.

    Article  PubMed  CAS  Google Scholar 

  27. Yang R, Li J, Jin J, Huang M, Yu Z, Xu X, et al. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Br J Haematol. 2017;176(1):101–10.

    Article  PubMed  CAS  Google Scholar 

  28. Gonzalez-Lopez TJ, Alvarez-Roman MT, Pascual C, Sanchez-Gonzalez B, Fernandez-Fuentes F, Jarque I, et al. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol. 2016;97(3):297–302.

    Article  PubMed  Google Scholar 

  29. Mazza P, Minoia C, Melpignano A, Polimeno G, Cascavilla N, Di Renzo N, et al. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol. 2016;95(2):239–44.

    Article  PubMed  CAS  Google Scholar 

  30. Elgebaly AS, Ashal GE, Elfil M, Menshawy A. Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia. Clin Appl Thromb Hemost. 2017;23(8):928–37. https://doi.org/10.1177/1076029616663849.

    Article  PubMed  CAS  Google Scholar 

  31. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (London, England). 2008;371(9610):395–403.

    Article  CAS  Google Scholar 

  32. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161–71.

    Article  PubMed  CAS  Google Scholar 

  33. George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009;144(3):409–15.

    Article  PubMed  CAS  Google Scholar 

  34. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag DR, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889–99.

    Article  PubMed  CAS  Google Scholar 

  35. Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118(16):4338–45.

    Article  PubMed  CAS  Google Scholar 

  36. Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411–23.

    Article  PubMed  CAS  Google Scholar 

  37. Cines DB, Gernsheimer T, Wasser J, Godeau B, Provan D, Lyons R, et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. Int J Hematol. 2015;102(3):259–70.

    Article  PubMed  CAS  Google Scholar 

  38. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25–33.

    Article  PubMed  Google Scholar 

  39. Godeau B, Porcher R, Fain O, Lefrere F, Fenaux P, Cheze S, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999–1004.

    Article  PubMed  CAS  Google Scholar 

  40. Arnold DM, Heddle NM, Carruthers J, Cook DJ, Crowther MA, Meyer RM, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012;119(6):1356–62.

    Article  PubMed  CAS  Google Scholar 

  41. Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol. 2012;158(3):386–98.

    Article  PubMed  CAS  Google Scholar 

  42. Patel VL, Mahevas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Bussel JB, Lee CS, Seery C, Imahiyerobo AA, Thompson MV, Catellier D, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than 2 years duration. Haematologica. 2014;99(7):1264–71.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Khellaf M, Charles-Nelson A, Fain O, Terriou L, Viallard JF, Cheze S, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228–36.

    Article  PubMed  CAS  Google Scholar 

  45. Ghanima W, Khelif A, Waage A, Michel M, Tjonnfjord GE, Romdhan NB, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2015;385(9978):1653–61.

    Article  CAS  Google Scholar 

  46. Fianchi L, Rossi E, Murri R, De Stefano V, Pagano L, Leone G. Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. Ann Hematol. 2007;86(3):225–6.

    Article  PubMed  Google Scholar 

  47. Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93(6):930–3.

    Article  PubMed  CAS  Google Scholar 

  48. Zhou H, Xu M, Qin P, Zhang HY, Yuan CL, Zhao HG, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2015;125(10):1541–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623–34.

    Article  PubMed  CAS  Google Scholar 

  50. Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B, Mazzucconi MG, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica. 2005;90(1):72–7.

    PubMed  Google Scholar 

  51. Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013;121(23):4782–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol. 1990;74(2):223–8.

    Article  PubMed  CAS  Google Scholar 

  53. Emilia G, Morselli M, Luppi M, Longo G, Marasca R, Gandini G, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002;99(4):1482–5.

    Article  PubMed  CAS  Google Scholar 

  54. Maloisel F, Andres E, Zimmer J, Noel E, Zamfir A, Koumarianou A, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med. 2004;116(9):590–4.

    Article  PubMed  CAS  Google Scholar 

  55. Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy JF, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol. 2005;75(1):60–4.

    Article  PubMed  CAS  Google Scholar 

  56. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3–40.

    PubMed  CAS  Google Scholar 

  57. Szczepanik AB, Sikorska A, Slomkowski M, Konopka L. The use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients. Int J Lab Hematol. 2007;29(5):347–51.

    Article  PubMed  CAS  Google Scholar 

  58. Xiao S, Liu Q, Hou M. Comparative study between two bleeding grading systems of primary immune thrombocytopenia. Zhonghua Xue Ye Xue Za Zhi. 2017;38(5):394–8.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Alexandra H. Marshall (of Marshall Medical Communications) provided editorial assistance to the authors during preparation of this manuscript.

Author information

Authors and Affiliations

  1. Department of Hematology, Qilu Hospital, Shandong University, Jinan, 250012, China

    Xin-guang Liu, Jun Peng & Ming Hou

  2. General Hospital of Ningxia Medical University, Yinchuan, China

    Xiao-chuan Bai

  3. Xiangya Hospital, Centre South University, Changsha, China

    Fang-ping Chen

  4. Zhongshan Hospital, Fudan University, Shanghai, China

    Yun-feng Cheng

  5. The First Affiliated Hospital of Soochow University, Suzhou, China

    Ke-sheng Dai & Yue Han

  6. The First Affiliated Hospital of Dalian Medical University, Dalian, China

    Mei-yun Fang

  7. Qinghai Provincial People’s Hospital, Xining, China

    Jian-Ming Feng

  8. West China Hospital, Sichuan University, Chengdu, China

    Yu-ping Gong

  9. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Tao Guo & Yu Hu

  10. The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, China

    Xin-hong Guo

  11. Harbin the Fourth Hospital, Harbin, China

    Luo-jia Hong

  12. Northern Jiangsu People’s Hospital, Yangzhou, China

    Bao-lai Hua

  13. The First Affiliated Hospital of Nanchang University, Nanchang, China

    Rui-bing Huang

  14. The First Hospital of Chinese Medical University, Shenyang, China

    Yan Li

  15. Xijing Hospital, The Fourth Military Medical University, Xi’an, China

    Mi-mi Shu

  16. Nanfang Hospital, Nanfang Medical University, Guangzhou, China

    Jing Sun

  17. Xinqiao Hospital, The Third Military Medical University, Chongqing, China

    Pei-yan Sun

  18. Peking University People’s Hospital, Beijing, China

    Yu-qian Sun

  19. Sichuan Provincial People’s Hospital, Chengdu, China

    Chun-sen Wang

  20. Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Shu-jie Wang & Tie-nan Zhu

  21. People’s Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China

    Xiao-min Wang

  22. Hainan Provincial People’s Hospital, Haikou, China

    Cong-ming Wu

  23. Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China

    Wen-man Wu

  24. Affiliated Hospital of North China University of Science and Technology, Tangshan, China

    Zhen-yu Yan

  25. Union Hospital of Fujian Medical University, Fuzhou, China

    Feng-e Yang

  26. The Second Hospital of Shanxi Medical University, Taiyuan, China

    Lin-hua Yang

  27. Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China

    Ren-Chi Yang & Lei Zhang

  28. The First People’s Hospital of Yunnan Province, Kunming, China

    Tong-hua Yang

  29. The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    Xu Ye

  30. The Second Xiangya Hospital, Central South University, Changsha, China

    Guang-sen Zhang

  31. Anhui Provincial Hospital, Hefei, China

    Chang-cheng Zheng

  32. Henan Cancer Hospital, Zhengzhou, China

    Hu Zhou

  33. Chengdu Women and Children’s Hospital, Chengdu, China

    Min Zhou

  34. Nanjing Drum Tower Hospital, Nanjing, China

    Rong-fu Zhou

  35. The Second Affiliated Hospital of Kunming Medical University, Kunming, China

    Ze-ping Zhou

  36. Chinese PLA General Hospital, Beijing, China

    Hong-li Zhu

Authors
  1. Xin-guang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiao-chuan Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fang-ping Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yun-feng Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ke-sheng Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mei-yun Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jian-Ming Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yu-ping Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tao Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xin-hong Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yue Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Luo-jia Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yu Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Bao-lai Hua
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Rui-bing Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Yan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Jun Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Mi-mi Shu
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Jing Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Pei-yan Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Yu-qian Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Chun-sen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Shu-jie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Xiao-min Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Cong-ming Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Wen-man Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Zhen-yu Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Feng-e Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Lin-hua Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Ren-Chi Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. Tong-hua Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. Xu Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  33. Guang-sen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  34. Lei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  35. Chang-cheng Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  36. Hu Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  37. Min Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  38. Rong-fu Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  39. Ze-ping Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  40. Hong-li Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  41. Tie-nan Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  42. Ming Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ming Hou.

Ethics declarations

Conflict of interest

The authors have no competing financial interests to declare.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 421 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Xg., Bai, Xc., Chen, Fp. et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia. Int J Hematol 107, 615–623 (2018). https://doi.org/10.1007/s12185-018-2445-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-018-2445-z

Keywords

Search

Navigation